Saroglitazar may reduce the requirement of insulin dose during the treatment of diabetic dyslipidemia by Amitesh Kumar Chatterjee

Subjects: “…Saroglitazar…”
Get full text

Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center exp... by Sujit Chaudhuri, Agnibha Dutta, Sunil Baran Das Chakraborty

Subjects: Get full text

Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients by Sadanand R. Shetty, Soumitra Kumar, R.P. Mathur, Kamal H. Sharma, Ashok D. Jaiswal

Subjects: “…Saroglitazar…”
Get full text

From Crisis to Diagnosis: A Case of Hypertriglyceridemic Pancreatitis as the First Clinical Presentation of Type 1 Diabetes by Subashini Vadivel, Sheetal Nandha Kishore, Jagannath S Dhadwad, Janvi Panchal

Subjects: Get full text

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease by Shotaro Kamata, Akihiro Honda, Isao Ishii

Subjects: Get full text

Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone? by Srinivasa P Munigoti, C V Harinarayan

Subjects: Get full text

Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling by Reza Afarin, Negar Dinarvand, Hossein Azizi Dariuni, Ghazal Orak, Bahar Jaberian Asl, Reza Azizi, Azam Khedri

Subjects: Get full text

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales by Francesca Colapietro, M. Eric Gershwin, Ana Lleo

Subjects: Get full text

Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice by Deepika Kumari, Jyoti Gautam, Vipin Sharma, Sonu Kumar Gupta, Soumalya Sarkar, Pradipta Jana, Vikas Singhal, Prabhakar Babele, Parul Kamboj, Sneh Bajpai, Ruchi Tandon, Yashwant Kumar, Madhu Dikshit

Subjects: Get full text

Suppression of TGF-β/Smad3 signaling pathway by Capparis spinosa and quercetin in a rat model of nonalcoholic steatohepatitis by Reza Afarin, Mahdi Hatami, Sajad Monjezi, Fatemeh Bineshfar, Akram Ahangarpour

Subjects: Get full text

Healing Effects of Saroglitazar Gel in Thermally Induced Burn in Rats by Aram Ibrahim, Hawkar Baiz, Zheen Ahmed, Hemn Othman, Tavga Aziz

Subjects: “…saroglitazar…”
Get full text

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evide... by Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil, Ashok Jaiswal

Subjects: “…Saroglitazar…”
Get full text

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis by Rasoul Akbari, Tahereh Behdarvand, Reza Afarin, Hamid Yaghooti, Mohammad Taha Jalali, Narges Mohammadtaghvaei

Subjects: “…Saroglitazar…”
Get full text

Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats by Reza Afarin, Negar Dinarvand, Bahar Jaberian Asl, Ghazal Orak, Elham Shakerian, Fatemeh Bineshfar, Akram Ahangarpour

Subjects: Get full text

Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: Plausible role of NLRP3 inflammasome and NF- κB by Sayima Nabi, Uma Bhandari, Syed Haque

Subjects: Get full text

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double bli... by Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar

Subjects: Get full text